Analysts Viewpoint
An Analysis of Viridian Therapeutics Inc (VRDN)’s Potential Price Growth
Viridian Therapeutics Inc’s recent filing unveils that its Chief Operating Officer Beetham Thomas W. acquired Company’s shares for reported $0.12
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.